• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to navigation
Close Ad

The Spoon

Daily news and analysis about the food tech revolution

  • Home
  • Podcasts
  • Events
  • Newsletter
  • Connect
    • Custom Events
    • Slack
    • RSS
    • Send us a Tip
  • Advertise
  • Consulting
  • About
The Spoon
  • Home
  • Podcasts
  • Newsletter
  • Events
  • Advertise
  • About

Cellular Agriculture

June 7, 2021

South Korea: Seawith Uses Algae for Serum and Scaffolding in Cultured Meat

It’s been a banner year so far for cultured meat. In addition to all of the funding that’s been flowing into the space since the start of 2021, there is also a growing number of startups from around the world attacking the issues of creating cell-based meat in unique ways.

The latest such startup to come to our attention is South Korea’s Seawith, which is leveraging algae to differentiate itself from other cultured meat players. The company uses algae to replace the fetal bovine serum (FBS) that has historically been used as a growth medium for cells. FBS is expensive and controversial, so most cell-based meat startups we cover are developing technologies that don’t require it. But Seawith is also using algae as a scaffolding to grow meat, which the company says yields thicker “cuts” of meat.

Following is a brief Q&A conducted via email with Heejae Lee, CTO of Seawith, who provides a little more insight into the company and what it is creating. Answers have been lightly edited for clarity.

1.) What makes Seawith different from other cell-based meat companies?
Seawith has the distinction of making the world’s first perfect steak at a price similar to slaughter meat. Based on algae engineering technology, it has replaced most of the bovine serum, which accounts for more than 90 percent of the cost of culturing meat, and the cell culture scaffold technology can make cultured meat thicker than 1cm.

2.) What makes algae so useful in creating cell-based meat?
The key principle of cultured meat is that one muscle cell takes nutrients and synthesizes them to make large meat. Algae is rich enough to be used as a nutritional supplement, which allows efficient cell culture by supplying it to cells. Also, algae are one of the most abundant resources on Earth, and they have the advantage of being cheap and available everywhere because they can grow anywhere with water and sunlight.

3.) Where are you at with your product right now?
We just finished our research and held a cultured meat tasting event. Cultured meat made with Korean bovine cells was evaluated well by attendees, who said it had the taste and aroma of beef, and the texture of meat could be seen. Currently, it is a muscle-only culture, but we are preparing various features such as taste of fat cells. We are preparing to get permission to produce enough to supply large quantities of products to restaurants by 2023.

4.) What types of cell-based meat will you be creating?
Seawith is making beef steak. There are many different types of meat, but the reason why we are making
difficult steaks is that only the technology we have can implement them. After perfecting the texture of muscle tissue, we plan to develop various meat products such as chicken, pig, and fish as well as meat products and animal feed.

5.) What is your timeline to bring your product to market?
We are currently discussing with the Ministry of Food and Drug Safety to make a trial sale in Korea with the aim of
launching a restaurant at the end of 2022. To this end, we are planning an urban cultured meat factory and will introduce a minimum production model by 2021. From 2023, we are preparing for local tasting event and product launch in different locations such as North America and Singapore.

June 7, 2021

The Food Tech Show: Upside’s Eric Schulze on the Intertwined Nature of Regulatory and Product Development in Cell-Based Meat

Back in 2016, Eric Schulze was working as an FDA regulator and happened upon a Reddit article discussing Memphis Meats’ cell-based meatball prototype. He was immediately fascinated with all the possibilities and challenges the company would encounter over the next few years.

Schulze reached out to the company’s cofounder and CEO, Uma Valeti. Memphis Meats (now called Upside) was looking for a scientist to help start the company’s embryonic cell line development and Schulze had the skills for the position. Before long, he was on his way to New York City where Valeti was giving a speech at the United Nations.

“I ran across Manhattan in a suit,” Schulze told me in a conversation on Clubhouse. Valeti “was of course poised and ready to go on stage. We had a great talk. He went back in and gave his talk. I accepted and I moved out to the west coast sight unseen.”

Schulze’s role in the company would eventually grow to encompass not only leading the company’s cell-based meat design, but also heading up regulatory oversight, an evolution that was very intentional and by design.

Valeti “made me a deal,” said Schulze. “He said, ‘You help me get the cell division off the ground. We’ll we’ll hand it off to someone later. But also, can you in parallel start thinking about how and how we’re going to build this regulatory system.”

You can hear the story of that early meeting, the thinking behind why Memphis changed its name to Upside, why the company chose chicken as its first product and much more on the latest episode of the Food Tech Show podcast.

Just click play below or find the show on Apple Podcasts, Spotify or wherever you get podcasts.

June 5, 2021

Cell-Based Breastmilk Startup TurtleTree Eyes Lactoferrin as First Commercial Product

TurtleTree, a startup developing human breastmilk using cellular agriculture technology, has announced that its first commercially available product will be lactoferrin, a protein found in both animal and cow milk.

Lactoferrin has long been viewed as a critical protein to both fight infection and to aid in brain development of young children, as well as a supplement to help women fight iron deficiencies, has more recently gained traction for its ability to help fight against COVID-19 infection.

While today’s supplement industry uses cow-derived lactoferrin, human breastmilk has 5-7 times the concentration. TurtleTree saw an opportunity.

“We have been able to identify early commercial ingredient targets due to our frequent conversations with prominent performance nutrition and infant formula companies,” said Max Rye, Chief Strategist of TurtleTree. “We’ve since seen tremendous interest from global partners in our portfolio of human and bovine milk products. It is going to be an exciting year for us.”

TurtleTree focus on lactoferrin as it’s first product for scaled commercial production doesn’t mean it’s giving up on creating fully realized cell-based breastmilk. The company is still working on its technology that grows mammary gland cells in a lab which actually lactate milk, but recognizes it could take a few years before cell-based milk can scale and has full regulatory approval.

TurtleTree isn’t the only cell-based breastmilk startup to make the news lately. Earlier this week BioMILQ announced that it has successfully made human breast milk outside the breast. Another, Israel-based BioMilk, is looking to create both human and cow milk analogs and recently became publicly listed on Tel Aviv stock exchange despite being few years out still from commercially scaled production.

Previous

Primary Sidebar

Footer

  • About
  • Sponsor the Spoon
  • The Spoon Events
  • Spoon Plus

© 2016–2025 The Spoon. All rights reserved.

  • Facebook
  • Instagram
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
 

Loading Comments...